Q3 2025 Dexcom Inc Earnings Call Transcript
Key Points
- DexCom Inc (DXCM) reported a 20% organic revenue growth in the third quarter of 2025 compared to the same period in 2024.
- The company has expanded CGM access and solidified its market share in both the US and international markets.
- DexCom Inc (DXCM) has established coverage for nearly 6 million type 2 non-insulin lives in the US, representing about half of the type 2 NIT commercial population.
- The introduction of DexCom Smart Basal aims to improve basal insulin titration and management, potentially enhancing adherence and reducing workflow for healthcare providers.
- DexCom Inc (DXCM) achieved its highest quarterly earnings per share in company history, with a net income of $242.5 million or $0.61 per share.
- The company's gross profit margin decreased to 61.3% from 63.0% in the third quarter of 2024, impacted by higher-than-expected scrap rates at manufacturing facilities.
- There were deployment challenges with the G7 sensors earlier in the year, which affected new customer starts and required additional scrutiny of supplied products.
- DexCom Inc (DXCM) had to invest in expedited shipping due to supply chain issues, impacting overall costs.
- The company lowered its 2025 non-GAAP gross profit margin guidance to approximately 61% due to ongoing scrap dynamics.
- Despite improvements, there were still some concerns about G7 sensor performance, including Bluetooth connectivity and adhesive issues.
Ladies and gentlemen, welcome to the DexCom third quarter 2025 earnings release conference call. My name is Abby, and I will be your operator for today's call. (Operator Instructions) As a reminder, the conference is being recorded. I will now turn the call over to Sean Christensen, Vice President of Finance and Investor Relations. You may begin.
Thank you, operator, and welcome to DexCom's third quarter 2025 earnings call. Our agenda begins with Jake Leach, DexCom's President and Interim CEO, who will summarize our recent highlights and ongoing strategic initiatives followed by a financial review and outlook from Jereme Sylvain, our Chief Financial Officer.
Following our prepared remarks, we will open the call up for your questions. At that time, we ask analysts to limit themselves to one question each so we can provide an opportunity for everyone participating today. Please note that there are also slides available related to our third quarter 2025 performance on the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
